A few months in­to his new role at At­tralus, ex-Pur­due chief Mark Tim­ney leads the biotech to a $116M round

Months af­ter Bay Area start­up At­tralus tapped Mark Tim­ney to its helm, the ex-Pur­due Phar­ma chief has led the com­pa­ny to a $116 mil­lion Se­ries B round — and with it, ac­tivist in­vestor Alex Den­ner is join­ing the board.

Tim­ney says he’ll use the funds to push At­tralus’ pan-amy­loid re­moval ther­a­pies for sys­temic amy­loi­do­sis in­to the clin­ic, as well as what he claims is the first amy­loi­do­sis-spe­cif­ic di­ag­nos­tic imag­ing agent.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER